MARKET

MGNX

MGNX

Macrogenics Inc
NASDAQ
3.000
-0.120
-3.85%
Closed 18:13 03/13 EDT
OPEN
3.180
PREV CLOSE
3.120
HIGH
3.250
LOW
2.970
VOLUME
1.03M
TURNOVER
0
52 WEEK HIGH
3.540
52 WEEK LOW
0.9897
MARKET CAP
190.67M
P/E (TTM)
-2.5391
1D
5D
1M
3M
1Y
5Y
1D
Stifel Nicolaus Sticks to Its Hold Rating for MacroGenics (MGNX)
TipRanks · 4d ago
MacroGenics Reaches Analyst Target Price
NASDAQ · 4d ago
MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative
Simply Wall St · 5d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 5d ago
Macrogenics Price Target Raised to $4.00/Share From $3.00 by Barclays
Dow Jones · 5d ago
Macrogenics Is Maintained at Overweight by Barclays
Dow Jones · 5d ago
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4
Benzinga · 5d ago
MACROGENICS <MGNX.O>: BARCLAYS RAISES TARGET PRICE TO $4 FROM $3
Reuters · 5d ago
More
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

Webull offers MacroGenics Inc stock information, including NASDAQ: MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.